Musculoskeletal Adverse Events Following BCMA CAR T-Cell Therapy in Multiple Myeloma: Clinical Characteristics and Immune Correlates.

Saved in:
Bibliographic Details
Title: Musculoskeletal Adverse Events Following BCMA CAR T-Cell Therapy in Multiple Myeloma: Clinical Characteristics and Immune Correlates.
Authors: Feng A; Department of Medicine, Duke University Medical Center, Durham, NC, USA., Wu J; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA., Choi T; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA., Wang X; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA., Bellavia T; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA., Burcher K; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA., Jones L; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA., Schrum D; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA., Eberwein E; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA., Cheng S; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA., Mathews P; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA., Jabbar S; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA., Coring T; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA., Gasparetto C; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA., Chase CC; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA., Long G; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA., Kirby S; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA., Lin C; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA., Huggins J; Division of Infectious Diseases, Duke University Medical Center, Durham, NC, USA., Tam P; Division of Infectious Diseases, Duke University Medical Center, Durham, NC, USA., Rowe-Nichols K; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA., Kang Y; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA. Electronic address: yubin.kang@duke.edu.
Source: Transplantation and cellular therapy [Transplant Cell Ther] 2026 May; Vol. 32 (5), pp. 559.e1-559.e11. Date of Electronic Publication: 2026 Feb 18.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101774629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-6367 (Electronic) Linking ISSN: 26666367 NLM ISO Abbreviation: Transplant Cell Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2666-6367
DOI:10.1016/j.jtct.2026.02.009